MedTrace Logo

Ultrasonography Assessment of Septic Arthritis on Native Joint

NCT02018952 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2016-03-25

No results posted yet for this study

Summary

The aim of this trial is to study the interest of ultrasonography among patients with septic arthritis.

Currently, ultrasonography is useful for detecting small fluid effusions, for examining otherwise inaccessible joints, such as the hip and for helping the joint aspiration.

Accurate assessment of disease activity and joint damage in septic arthritis is important for monitoring treatment efficiency and for prediction of the outcome of the disease.

Nowadays, magnetic resonance imaging (MRI) provides better resolution than radiography or tomography for the detection of joint effusion and for differentiation between bone and soft tissue infectious. The sensibility is reported to be nearly 100% with a specificity of more than 75%.

However, MRI is expensive and not rapidly accessible.

Therefore, ultrasonography, a non invasive, painless, inexpensive, and non radiating exam can be used to assess the presence and extent of inflammation, destruction, and tissue response.

The objective is to describe, using ultrasonography, the abnormalities joint structure influenced the septic arthritis evolution and prognosis.

The investigators hope, at the end of this study, to evaluate ultrasonography interest in septic arthritis and to establish ultrasonography prognosis factors to predict treatment efficiency and functional outcome.

Conditions

  • Septic Arthritis

Interventions

OTHER

Ultrasonography assessment

All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group). Day 0 : * Information of patient and no opposition getting * Clinical exam * Laboratory tests * Radiography of the targeted joint * Ultrasonography of the targeted joint and controlateral joint (about 20 minutes) Day 4 : * Clinical exam * Laboratory tests * Ultrasonography of the targeted joint and controlateral joint (about 20 minutes) Day15 : * Clinical exam * Laboratory tests * Ultrasonography of the targeted joint and controlateral joint (about 20 minutes) M3 : * Clinical exam * Laboratory tests * Radiography of the targeted joint * Ultrasonography of the targeted joint and controlateral joint (about 20 minutes) * Functional outcome

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Benoît LE GOFF, Doctor · Nantes University Hospital

  • Grégoire CORMIER, Doctor · CHD La Roche sur Yon

  • Oriane MEROT, Doctor · CH Saint-Nazaire

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018952 on ClinicalTrials.gov